Handing over a regulated pharma family business to the next generation
First-generation founders in Indian pharma and chemicals face a unique succession challenge — handing over a regulated, audit-heavy operating business. What works, what doesn't.
Indian family enterprises in pharma and fine chemicals face a succession challenge that is materially different from a trading or distribution family business. Trading and distribution can be handed over with relationships, capital allocation and operating instinct intact. Regulated manufacturing has a fourth layer — the institutional knowledge of how the plant runs, what the audit history looks like, how the customer chemistry has evolved across batches over years. That layer is much harder to transfer. I want to share what I think about this — both for the Laksh family and for the wider community of first-generation Indian pharma founders thinking about the next decade.
What is different about regulated manufacturing
A trading family business runs on a network of customer and supplier relationships, capital discipline and trust built over decades. A pharma manufacturer runs on all of that — plus a plant whose operating history is, itself, the moat. The QC records from five years ago matter to the audit happening today. The deviation patterns over the last three years are what the regulator is reading into. The customer's familiarity with how a given batch behaves in their downstream process is institutional knowledge that lives in your operations team, your QC laboratory and — yes — in the founder's own running understanding of the plant.
All of this means a regulated-pharma family business cannot be handed over the way a trading firm can. The transition has to be designed.
Start the transition early
The single most important factor in a successful pharma family-business transition is time. Second-generation members who join the business at 35 with no operating exposure cannot run a regulated plant at 50. The right pattern is exposure from the early twenties — operations rotations, QC laboratory time, regulatory affairs participation, customer audit attendance. The next generation needs to absorb the plant's history while it is still being written.
Specialise, don't dilute
Multi-member next-generation transitions in regulated pharma work when each member specialises into a distinct function — one runs operations, one runs commercial, one runs new-product development, one runs compliance and regulatory. They work poorly when the next generation comes in as a group of generalists who informally re-litigate every decision. Indian pharma family enterprises that survive across generations have, almost without exception, structured the second-generation roles with clear functional ownership.
What the next generation has to add
Inheriting the plant is not enough. The next generation has to add something. In Indian regulated pharma in 2026, three additions matter most. One — modernising the digital backbone of the operations (electronic batch records, ERP integration, real-time QC instrumentation). Two — opening new export geographies the first generation did not have the time to develop (Japan, Korea, parts of Europe). Three — expanding into adjacent regulated categories that fit the plant's chemistry but were not on the first-generation product list (newer APIs, new chiral chemistries, specialised intermediates).
If the next generation inherits and modernises, the business compounds for another decade. If they inherit and only operate, the business slowly stagnates as the founder generation steps back.
The founder's letting-go
The hardest part of this transition is the founder's. The plant was built from scratch — every supplier relationship, every customer audit, every product line, every QC protocol. Letting go is hard for a reason that the next generation rarely fully grasps. The right framing is that the founder does not let go of the business; the founder lets go of certain decisions, and retains a different role — strategic stewardship, customer relationships at the senior level, mentorship of the operating team. The transition is not a single handover event. It is a multi-year migration of decision rights, and it works when both the founder and the next generation accept that timeline.
For Indian SME founders thinking about this
If you are a first-generation founder in pharma or fine chemicals thinking about the next ten years, three pieces of advice. One — start the conversation with the next generation now. Even if they are nineteen. The transition design has a fifteen-year horizon, not a five-year one. Two — invest in the institutional capability that the family does not personally have — strong functional heads, professional managers, a credible compliance and regulatory team. The business should be able to run for a quarter without any family member in the building. Three — be honest about what the next generation actually wants. Forced succession breaks family businesses faster than any market shock.
Got a question on what you've just read — or a project that touches one of the categories above? Write directly to the office.
First-generation Indian industrialist. Founder and Managing Director of Laksh Finechem — a WHO-GMP, FDA and ISO-certified manufacturer of APIs, iodine derivatives and specialty chemicals.